Skip to contentA
Axim Biotechnologies, Inc.
A
AXIMAxim Biotechnologies, Inc. Q1 2024 · 10-Q
Revenue$52.98K$52.98K+616.2% vs Q1 2023 Net Income-$292.30K-$292.30KN/M vs Q1 2023 EPS Diluted-$0.00-$0.00N/M vs Q1 2023 Operating Income-$401,563N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Axim Biotechnologies, Inc. · CIK 1514946 · Engraved from SEC EDGAR
Free Cash Flowderived-$255,345— Margins · derivedOperating margin-758.0%+8849.1 pt vs Q1 2023
Net margin-551.7%+36796.2 pt vs Q1 2023
ended Mar 31, 2024 · filed May 20, 2024 · 50 d after period end